Publications

Optimizing flecainide plasma concentration profile for atrial fibrillation conversion while minimizing adverse ventricular effects by rapid, lowdose intratracheal or intravenous administration

A.A. Marum, et al. | International Journal of Cardiology 2018 We investigated whether rapid administration of a low dose of flecainide, either intratracheally or intravenously (IV), could accelerate conversion of atrial fibrillation (AF) while reducing adverse ventricular effects. Methods: Flecainide was delivered via intratracheal administration at...

Hand-held breath-actuated nebulizer for delivery of flecainide to the heart: Dose-concentration dependent pharmacokinetics and QRS interval prolongation of the inhaled flecainide in healthy volunteers.

Belardinelli | Circulation 2017; 136:A16836 Oral and IV routes for delivery of flecainide (FLEC) for acute cardioversion of atrial fibrillation (AF) have drawbacks: high doses (150-300 mg) and 2- to 4- hours wait time for cardioversion with oral dosing and hospitalization for IV administration. Studies in...

A novel approach to deliver flecainide to the heart: A study in healthy volunteers to compare the cardiovascular effects of inhaled vs intravenous flecainide

Belardinelli | Circulation 2017; 136:A16888 Flecainide (FLEC) is effective for cardioversion of recentonset atrial fibrillation (AF). In dogs and pigs intratracheal instillation of FLEC is effective in terminating episodes of AF within minutes. The present study is part of a drug development program to use inhaled...